Angiotensin II does not directly affect Aβ secretion or β-/γ-secretase activity via activation of angiotensin II type 1 receptor

Neuroscience Letters

Volumn 500, Issue 2, 2011, Pages 103-107

  Wang, Bian Rong ^a,b   Shi, Jian Quan ^a   Zhang, Ying Dong ^a   Zhu, Dong Lin ^a   Shi, Jing Ping ^a,b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

secretase; Alzheimer's disease; Amyloid beta; Angiotensin II; Angiotensin II type 1 receptor

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA SECRETASE; GAMMA SECRETASE; LOSARTAN; MESSENGER RNA; PRESENILIN 1;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HIPPOCAMPUS; HORMONE ACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CELL CULTURE; NERVE CELL CULTURE; NEWBORN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; RECEPTOR BLOCKING; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; LOSARTAN; NEURONS; PEPTIDE FRAGMENTS; PRESENILIN-1; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSFECTION;

EID: 79960472517     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.014     Document Type: Article

References (23)

1. Armando I., Volpi S., Aguilera G., Saavedra J.M. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotrophin-releasing factor response to isolation stress. Brain Res. 2007, 1142:92-99.
2. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
3. Danielyan L., Klein R., Hanson L.R., Buadze M., Schwab M., Gleiter C.H., Frey W.H. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010, 13:195-201.
4. Díaz-Ruiz C., Wang J., Ksiezak-Reding H., Ho L., Qian X., Humala N., Thomas S., Martínez-Martín P., Pasinetti G.M. Role of hypertension in aggravating Aβ neuropathology of AD type and Tau-mediated motor impairment. Cardiovasc. Psychiatry Neurol. 2009, 2009:107286.
5. Elkins J.S., Douglas V.C., Johnston S.C. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 2004, 62:363-368.
6. Farmery M.R., Tjernberg L.O., Pursglove S.E., Bergman A., Winblad B., Näslund J. Partial purification and characterization of gamma-secretase from post-mortem human brain. J. Biol. Chem. 2003, 278:24277-24284.
7. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L., LaFerla F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2006, 26:9047-9056.
8. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
9. Inaba S., Iwai M., Furuno M., Tomono Y., Kanno H., Senba I., Okayama H., Mogi M., Higaki J., Horiuchi M. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009, 53:356-362.
10. Kehoe P.G., Russ C., McIlory S., Williams H., Holmans P., Holmes C., Liolitsa D., Vahidassr D., Powell J., McGleenon B., Liddell M., Plomin R., Dynan K., Williams N., Neal J., Cairns N.J., Wilcock G., Passmore P., Lovestone S., Williams J., Owen M.J. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat. Genet. 1999, 21:71-72.
11. Kehoe P.G., Katzov H., Feuk L., Bennet A.M., Johansson B., Wiman B., de Faire U., Cairns N.J., Wilcock G.K., Brookes A.J., Blennow K., Prince J.A. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum. Mol. Genet. 2003, 12:859-867.
12. Kehoe P.G., Miners S., Love S. Angiotensins in Alzheimer's disease - friend or foe?. Trends Neurosci. 2009, 32:619-628.
13. Lehmann D.J., Cortina-Borja M., Warden D.R., Smith A.D., Sleegers K., Prince J.A., van Duijn C.M., Kehoe P.G. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am. J. Epidemiol. 2005, 162:305-317.
14. Li N.C., Lee A., Rhitmer R.A., Kivipelto M., Lawler E., Kazis L.E., Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010, 340:b5465.
15. Miners J.S., Ashby E., Van Helmond Z., Chalmers K.A., Palmer L.E., Love S., Kehoe P.G. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2008, 34:181-193.
16. Mogi M., Li J.M., Tsukuda K., Iwanami J., Min L.J., Sakata A., Fujita T., Iwai M., Horiuchi M. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem. Biophys. Res. Commun. 2008, 375:446-449.
17. Narain Y., Yip A., Murphy T., Brayne C., Easton D., Evans J.G., Xuereb J., Cairns N., Esiri M.M., Furlong R.A., Rubinsztein D.C. The ACE gene and Alzheimer's disease susceptibility. J. Med. Genet. 2000, 37:695-697.
18. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., Song M., Xiong J., Bai Y., Pei G. Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation. Nat. Med. 2006, 12:1390-1396.
19. Savaskan E., Hock C., Olivieri G., Bruttel S., Rosenberg C., Hulette C., Müller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol. Aging 2001, 22:541-546.
20. Takeda S., Sato N., Takeuchi D., Kurinami H., Shinohara N., Niisato K., Kano M., Ogihara T., Rakugi H., Morishita R. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009, 54:1345-1352.
21. Tota S., Kamat P.K., Awasthi H., Singh N., Raghubir R., Nath C., Hanif K. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav. Brain Res. 2009, 199:235-240.
22. Wang J., Ho L., Chen L., Zhao Z., Zhao W., Qian X., Humala N., Seror I., Bartholomew S., Rosendorff C., Pasinetti G.M. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 2007, 117:3393-3402.
23. Zhu D., Shi J., Zhang Y., Wang B., Liu W., Chen Z., Tong Q. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One 2011, 6:e16037.